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L E T T E R TO TH E ED I TO R
Why just detect?We can protect: A letter to the authors of
“Prevention of left atrium esophagus fistula”
Dear Sir,
We read the article by Jiang et al,1 with great interest. The authors
have provided an overview of technologies and strategies to minimise
esophageal injury during ablation for atrial fibrillation that is compre-
hensive. We would like to share recently available data on thermal
protection that would not have been available when they wrote their
manuscript but may add to the discussion on the topic reviewed by
Jiang et al. Atrio-esophageal fistula remains a major cause of mortality
from theseprocedures, so considerationof all information is important.
In their review, Jiang et al explore the current methods routinely
used to minimise esophageal injury: restraint in applying force and
power, deflection of the esophagus away from the site of energy
application, monitoring of temperature and inhibition of gastric acid
production. A large part of the review is devoted to methods of tem-
perature measurement, although these have an obvious flaw: they
may predict the occurrence of injury, but do not directly protect the
threatened tissue. Esophageal temperature monitoring probes aim to
detect temperature rise but even this ability may vary between differ-
ent types of commercially available esophageal temperature monitor-
ing probes.2
Esophageal cooling was explored briefly in this article, noting that
various forms of cooling based on local infusion of cold water have
shown some benefit in reducing esophageal injury, but that results
were inconsistent. A recent systematic review and meta-analysis of
these methods give a more favourable impression: despite the lim-
ited heat-extraction capability of water-infusion, a small but significant
reduction in esophageal injury is evident on meta-analysis when com-
pared to controls.3
These early studies on esophageal cooling showed promise; this
led us to design and conduct the recently completed IMPACT study
(NCT03819946),4,5 which may be of interest to the authors and jour-
nal readers. This double-blind randomised trial evaluated a controlled
method of esophageal cooling during Atrial Fibrillation (AF) ablation
compared to standard care; at the study site this consisted of a single
sensor esophageal temperature monitoring probe was the standard of
care.
The EnsoETM device was utilised in the IMPACT study to deliver
controlled esophageal cooling. This device is already in routine clini-
cal use as amethod of controlling body temperature via the esophagus,
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providing therapeutic hypo/normothermia in patients who are recov-
ering from traumatic brain injury or are susceptible to hyperpyrexia.6
The physical profile of the device and its insertion are similar to that
of an orogastric tube; it is a silicone, multi-lumen probe, and when the
non-patient end is connected to a mobile console, it allows distilled
water to flow in a closed loop system. The temperature of the water
can be set and controlled at 4-42◦C, depending on the clinical indica-
tion. In IMPACT, it was set at 4◦C for the whole duration of posterior
ablation.
The EnsoETM is irrigated at 2.4 L/min, giving a capacity to control
local temperature that is more powerful and more precise that can be
accomplished by direct infusion of water. The concern raised by Jiang
et al about instrumentation of the esophagus is certainly relevant to
devices designed to deviate the esophagus, which can be a delicate
structure, but may be less concerning for the EnsoETM device as it
exerts minimal force and is commonly used for many days at a time in
its established role.
The design of the IMPACT study included 1:1 randomisation to
the protected group with the esophageal cooling device or to stan-
dard of care during their AF ablation. All participants were required to
attend a follow-up endoscopic examination after the ablation. Patients
and endoscopists were blinded to the results of the randomization. As
esophageal injury was a risk to all those receiving left atrial ablations,
regardless of ablation methodology or type of AF, all those previously
screened at our centre as being appropriate for ablation treatment
under general anaesthesia were subsequently approached for poten-
tial recruitment to the study. The results therefore reflect real-world
management of risk for all those attending forAFablation. The ablation
operators were not blinded, as the EnsoETMdevice is clearly visible on
fluoroscopy. All ablations were in line with normal practice using the
ablation parameters customary at our centre andwere guided byAbla-
tion Index, a recognised marker of lesion quality. The ablations were
performed using Thermocool Smart Touch Surround Flow (Biosense
Webster Inc., Irvine, CA) irrigated contact force sensing catheters at
30W and 350 AI posteriorly and 40Wat≥450 AI anteriorly.
The IMPACT study was completed in January 2020 with long-term
follow-up results awaited. A total of 188 participants were enrolled,
with 120 completing endoscopy after the ablation procedure. In this
study, there were significantly fewer esophageal thermal injuries in
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patients protected by the EnsoETM device compared to controls,
with a risk reduction of 83.4%4 and without any evidence that the
device makes it any more difficult to achieve procedural end points.5
Blinded endoscopy reports showed that no instrument-related abra-
sive trauma occurred in the protected group. No case of hypothermia
and no adverse effect of the device were detected during or after any
ablation procedure. Complexity was not an issue during conduction
of the study: insertion of the device proved easier than the placement
of a transesophageal echo probe, and workflow of the procedure
was made slightly more efficient compared to using a temperature
probe.4
The process of cooling the esophagus while therapeutically heat-
ing the adjacent left atrium is inherently paradoxical. The possibility of
undermining the intended therapeutic effect is obvious: if the cooling
effect extends into the atrial myocardium, it could increase the diffi-
culty of achieving transmurality of lesions. Recently presented analysis
of the ablation data4 shows that this does not occur; procedural end
points and workflow were similar to the control group with no effect
on impedance drop, a surrogate for lesion depth (8.6 Ω [interquartile
range, IQR: 6-11.8] vs 8.76 Ω [IQR: 6-12.2] P = .25). Median ablation
catheter tip temperature was the same as the control group at 25.5
degrees. Short-term ablation end points were unaffected, but long-
term follow-up data are required to confirm how ablations performed
with esophageal cooling compared to standard care.
AF ablations are already expensive procedures, and cost is a factor
that must be considered when choosing equipment. The EnsoETM is
less expensive than some temperaturemonitoring probes but substan-
tially more than the cheapest models. With the benefit demonstrated
in the IMPACT trial and the great importance of avoiding esophageal
thermal injury, we now use the device routinely adjunct to previously
established equipment whenever possible.
Controlled esophageal temperature is a logical strategy for any
method of ablation that creates thermal injury. Accuratemeasurement
of temperature may help the operator to detect a temperature change
at an early stage; we believe that it makes more sense to actively pro-
tect the esophagus by taking control of the local temperature.
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